A warm sensor maintains skin barrier to prevent dehydration

Washington, May 15 (ANI): The TRPV4 ion channel in skin keratinocytes is important for formation and maintenance of barrier function to prevent dehydration, a new research has said.

Japanese research group led by Prof. Makoto Tominaga and Dr. Takaaki Sokabe (National Institute for Physiological Sciences: NIPS) found that TRPV4, one of the temperature-sensitive Ca2+-permeable channels, namely “thermoTRPs”, acts as a warm sensor to choose preferred environmental temperatures in mammals.

The research group sought the alternative function of TRPV4, since skin keratinocytes express another thermoTRP named TRPV3, which also functions as a warm sensor.

TRPV4 was found to interact with b-catenin, an adaptor protein between actin filaments and E-cadherin in cell-cell junction complex. When TRPV4 was genetically removed from keratinocytes, Ca2+-induced cell-cell junction formation was delayed and immature, resulting in leaky junctions.

Consistently, intercellular junction-dependent skin barrier in TRPV4-deficient mice became weak (leaky intercellular pathway) compared to wild-type mice. Interestingly, these phenotypes were TRPV4-specific, but not TRPV3-dependent.

Dr. Sokabe said, “TRPV4 may utilize skin temperature to provide Ca2+ for cell-cell junction complexes to reinforce their tightness. For instance, dried skin in cold seasons or regions could be due to low activity of TRPV4 caused by low skin temperature. Development of chemicals modulating TRPV4 activity would be useful for barrier repair of damaged skin.” (ANI)

Drug combo destroys precancerous colon polyps, sparing normal tissue

London, March 29 (ANI): American researchers have identified a two-drug combination that can kill precancerous colon polyps even as it spares normal tissue.

The study, conducted by a team of scientists at The University of Texas M. D. Anderson Cancer Center, has appeared in the advance online edition of the journal Nature.

The regimen, tested so far in mouse models and on human colon cancer tissue in the lab, appears to address a problem with chemopreventive drugs – they must be taken continuously long term to be effective, exposing patients to possible side effects, stated senior author Xiangwei Wu, associate professor in M. D. Anderson”s Department of Head and Neck Surgery.

Wu said: “This combination can be given short term and periodically to provide a long-term effect, which would be a new approach to chemoprevention.”

The researchers found that a combination of Vitamin A acetate (RAc) and TRAIL (tumour necrosis factor-related apoptosis-inducing ligand) kills precancerous polyps and inhibits tumor growth in mice that have deficiencies in a tumor-suppressor gene.

That gene, adenomatous polyposis coli (APC) and its downstream signaling molecules, are mutated or deficient in 80 percent of all human colon cancers, Wu pointed out.

Early experiments with APC-deficient mice demonstrated that the two drugs combined or separately did not harm normal colon epithelial cells.

Separately, they showed no effect on premalignant polyps called adenomas.

RAc and TRAIL together killed adenoma cells, causing programmed cell suicide know as apoptosis.

Researchers saw RAc sensitises polyp cells to TRAIL.

The scientists tracked the molecular cascade caused by APC deficiencies, and discovered that insufficient APC sensitises cells to TRAIL and RAc by suppressing a protein that blocks TRAIL.

APC-deficient mice were treated with 15 cycles of the RAc/TRAIL combination over six weeks. Others received either RAc or TRAIL and a control group received nothing.

A month later, control mice and those treated with one of the drugs averaged between 35 and 42 polyps, while those receiving the combination averaged 10.

To test the combination”s potential as short-term therapy, APC-deficient mice were treated with two cycles of the combination in one week, causing a 69 percent polyp reduction two weeks later.

A 10-fold increase in dose left treated mice with only 10 percent of the polyps found in controls.

A longer term test of relative survival using five treatments over four months improved survival from 186 days for controls to beyond 213 days for treated mice, with five of seven treated mice living more than eight months.

Thereafter, the research team treated biopsy samples of normal tissue and tumour regions from patients with familial adenomatous polyposis – an inherited condition that inevitably leads to colon cancer if the colon is not removed.

Treatment of normal tissue caused little cell death, while 57 percent of polyp cells were killed via apoptosis.

According to Wu, targeted therapies today aim at blocking some aspect of the tumor that drives its growth, whereas RAc and TRAIL together kill precancerous polyps outright.

Since APC is deficient or mutated in other types of cancer, the combination therapy could become a more general drug.

Wu said the team will conduct additional research to understand potential side effects before human clinical trials can be considered.

They will also try to develop an injectable version of the combination, which is administered intravenously now.

One of the genes activated by the APC-deficient pathway, ß-catenin, is involved with stem cell self-renewal and maintenance in adult tissues. The team conducted a series of experiments and determined that RAc/TRAIL does not affect stem cells in mice.

Wu said. “We hope this combination, if it proves to lack toxicities, might be available as a chemopreventive agent to a broader, general population.” (ANI)

Factor that boosts stem cell growth, regeneration identified

London, Mar 22 (ANI): A new growth factor has been found that stimulates the expansion and regeneration of hematopoietic (blood-forming) stem cells in culture and in laboratory animals, say Duke University Medical Center scientists.

The discovery could help researchers overcome one of the most frustrating barriers to cellular therapy— the fact that stem cells are so few in number and so stubbornly resistant to expansion.

According to researchers, umbilical cord blood could serve as a universal source of stem cells for all patients who need a stem cell transplant.

But the numbers of stem cells in cord blood units are limited, and thus there is a clinical need to develop a method to expand cord blood stem cells for transplantation purposes.

“Unfortunately, there are no soluble growth factors identified to date that have been proven to expand human stem cells for therapeutic purposes,” said Dr. John Chute.

The researchers found that adding pleiotrophin, a naturally-occurring growth factor, stimulated a ten-fold expansion of stem cells taken from the bone marrow of a mouse.

They also found that pleiotrophin increased the numbers of human cord blood stem cells in culture that were capable of engraftment in immune-deficient mice.

When they injected pleiotrophin into mice that had received bone marrow-suppressive radiation, they observed a 10-fold increase in bone marrow stem cells compared to untreated mice.

“These results confirmed that pleiotrophin induces stem cell regeneration following injury,” said Chute.

Chute said that the finding could lead to broader application of cord blood transplants for the large numbers of patients who do not have an immune-matched donor.

“Perhaps more importantly, systemic treatment with pleiotrophin may have the potential to accelerate recovery of the blood and immune system in patients undergoing chemotherapy or radiotherapy,” he said.

Given the potency of the effect of pleiotrophin on stem cell expansion, the authors examined whether pleiotrophin provoked blood-forming cells to become malignant.

Chute said that until now, they have not seen any evidence of cancer in mice up to six months after treatment with pleiotrophin.

The Duke team is already conducting further experiments to determine if pleiotrophin is necessary for normal stem cell growth and development, and Chute said that it will be important to conduct additional animal studies before moving into human clinical trials.

“At this point, any progress we can make that helps us better understand which biological pathways are activated in stem cells in response to pleiotrophin will help move the discovery forward,” he added.

The study has appeared in the journal Nature Medicine. (ANI)

”Mischievous” gut bugs could be making you fat

Washington, Mar 5 (ANI): You can blame bacteria in your stomach for those unwanted pounds. A new study claims that the bugs, which are found in the digestive tract, boost appetite.

They also appear to cause cholesterol and blood pressure problems and raise the odds of diabetes and liver disease, the study claims.

According to research being published online this week by Science magazine, increased appetite and insulin resistance can be transferred from one mouse to another via intestinal bacteria.

“It has been assumed that the obesity epidemic in the developed world is driven by an increasingly sedentary lifestyle and the abundance of low-cost high-calorie foods,” says senior author Andrew Gewirtz, PhD, associate professor of pathology and laboratory medicine at Emory University School of Medicine. “However, our results suggest that excess caloric consumption is not only a result of undisciplined eating but that intestinal bacteria contribute to changes in appetite and metabolism.”

The first author of the paper is Emory faculty member Matam Vijay-Kumar, PhD, who has been studying a mouse strain with an altered immune system. These mice were engineered to lack a gene, Toll-like receptor 5 (TLR5), which helps cells sense the presence of bacteria. TLR5 recognizes flagellin, the main component of the apparatus (flagella) that many bacteria use to propel themselves.

The study began with Emory researcher Jesse Aitken”s unexpected observation that TLR5-deficient mice are about 20 percent heavier than regular mice and have elevated triglycerides, cholesterol and blood pressure. They also have mildly elevated blood sugar and increased production of insulin, Vijay-Kumar and Gewirtz found. TLR5-deficient mice tended to consume about 10 percent more food than their regular relatives. When their food was restricted they lost weight but still had a decreased response to insulin (i.e. insulin resistance). When fed a high-fat diet, TLR5-deficient mice gained more weight than regular mice and, moreover, developed full-blown diabetes and fatty liver disease. In short, TLR5-deficient mice exhibit “metabolic syndrome,” a cluster of disorders that in humans increases the risk of developing heart disease and diabetes.

Previous research has shown that TLR5 plays a prominent role in controlling bacteria in the intestine. Under certain conditions, many TLR5-deficient mice develop colitis, an inflammatory bowel disease, while the majority of the mice have chronic low-level inflammation.

“The intestine is like a complex community, with good and bad actors,” Gewirtz says. “We can think of TLR5 as being like a neighborhood police officer who can distinguish law-abiding residents from potential trouble makers. Take away TLR5, and the safety of the community deteriorates.”

Treating TLR5-deficient mice with strong antibiotics, enough to kill most of the bacteria in the intestine, reduces their metabolic abnormalities. This led Gewirtz”s team to analyze the composition of the intestinal bacteria of TLR5-deficient mice, collaborating with Ruth Ley at Cornell University.

Ley”s earlier research on mice and humans shows that obesity results in more bacteria of the Firmicutes family and less of the Bacteroidetes, which increases the intestine”s ability to harvest calories from food. In contrast, TLR5-deficient mice had normal proportions of Firmicutes and Bacteroidetes but differed in the bacterial species that comprised these families.

Importantly, Gewirtz and his team found that transfer of the intestinal bacteria from TLR5-deficient mice to regular mice transferred many of the characteristics of metabolic syndrome including increased appetite, obesity, elevated blood sugar, and insulin resistance. (ANI)

”Mischievous” gut bugs could be making you fat

Washington, Mar 5 (ANI): You can blame bacteria in your stomach for those unwanted pounds. A new study claims that the bugs, which are found in the digestive tract, boost appetite.

They also appear to cause cholesterol and blood pressure problems and raise the odds of diabetes and liver disease, the study claims.

According to research being published online this week by Science magazine, increased appetite and insulin resistance can be transferred from one mouse to another via intestinal bacteria.

“It has been assumed that the obesity epidemic in the developed world is driven by an increasingly sedentary lifestyle and the abundance of low-cost high-calorie foods,” says senior author Andrew Gewirtz, PhD, associate professor of pathology and laboratory medicine at Emory University School of Medicine. “However, our results suggest that excess caloric consumption is not only a result of undisciplined eating but that intestinal bacteria contribute to changes in appetite and metabolism.”

The first author of the paper is Emory faculty member Matam Vijay-Kumar, PhD, who has been studying a mouse strain with an altered immune system. These mice were engineered to lack a gene, Toll-like receptor 5 (TLR5), which helps cells sense the presence of bacteria. TLR5 recognizes flagellin, the main component of the apparatus (flagella) that many bacteria use to propel themselves.

The study began with Emory researcher Jesse Aitken”s unexpected observation that TLR5-deficient mice are about 20 percent heavier than regular mice and have elevated triglycerides, cholesterol and blood pressure. They also have mildly elevated blood sugar and increased production of insulin, Vijay-Kumar and Gewirtz found. TLR5-deficient mice tended to consume about 10 percent more food than their regular relatives. When their food was restricted they lost weight but still had a decreased response to insulin (i.e. insulin resistance). When fed a high-fat diet, TLR5-deficient mice gained more weight than regular mice and, moreover, developed full-blown diabetes and fatty liver disease. In short, TLR5-deficient mice exhibit “metabolic syndrome,” a cluster of disorders that in humans increases the risk of developing heart disease and diabetes.

Previous research has shown that TLR5 plays a prominent role in controlling bacteria in the intestine. Under certain conditions, many TLR5-deficient mice develop colitis, an inflammatory bowel disease, while the majority of the mice have chronic low-level inflammation.

“The intestine is like a complex community, with good and bad actors,” Gewirtz says. “We can think of TLR5 as being like a neighborhood police officer who can distinguish law-abiding residents from potential trouble makers. Take away TLR5, and the safety of the community deteriorates.”

Treating TLR5-deficient mice with strong antibiotics, enough to kill most of the bacteria in the intestine, reduces their metabolic abnormalities. This led Gewirtz”s team to analyze the composition of the intestinal bacteria of TLR5-deficient mice, collaborating with Ruth Ley at Cornell University.

Ley”s earlier research on mice and humans shows that obesity results in more bacteria of the Firmicutes family and less of the Bacteroidetes, which increases the intestine”s ability to harvest calories from food. In contrast, TLR5-deficient mice had normal proportions of Firmicutes and Bacteroidetes but differed in the bacterial species that comprised these families.

Importantly, Gewirtz and his team found that transfer of the intestinal bacteria from TLR5-deficient mice to regular mice transferred many of the characteristics of metabolic syndrome including increased appetite, obesity, elevated blood sugar, and insulin resistance. (ANI)

Gene linked to male infertility identified

Washington, Sept 16 (ANI): Scientists from Virginia Commonwealth University have identified a gene that may contribute to male infertility.

The research team hopes that the new findings would lead to new approaches to male contraception.

Sperm are produced in the testicles through a three-step process called spermatogenesis.

During the final stage, known as spermiogenesis, a lot of changes take place, including the packaging of DNA into the sperm head and the formation of the sperm tail, which propels the sperm cell toward the egg.

The study conducted using mouse model showed that mice lacking a protein called meiosis expressed gene 1, or MEIG1, were sterile as a result of impaired spermiogenesis – the process that encompasses changes in the sperm head and the formation of the tail.

The team also found that MEIG1 associates with the Parkin co-regulated gene protein, or PACRG protein, and that testicular PACRG protein is reduced in MEIG1-deficient mice.

PACRG is thought to play a key role in assembly of the sperm tail, and the reproductive phenotype of PACRG -deficient mice mirrors that of the MEIG1-mutant mice.

“We discovered that MEIG1 is essential for male fertility. Moreover, our findings reveal a critical role for the MEIG1/PACRG partnership in the function of a structure that is unique to sperm, the manchette. The absence of a normal manchette in mice lacking MEIG1 totally disrupts the maturation process of sperm,” said Dr Jerome F. Strauss III, dean in the VCU School of Medicine.

“In addition to having an impact on fertility, the discovery identifies a new target for drug discovery for a much needed reversible male method of contraception,” he added.

The study is published in the Early Edition of the Proceedings of the National Academy of Sciences. (ANI)

New treatment for acute myeloid leukaemia developed

Washington, July 7 (ANI): Australian and Canadian researchers have developed a new therapy that specifically targets cancer stem cells in acute myeloid leukaemia.

The new treatment targets a protein, CD123, on the surface of cancer stem cells that drive acute myeloid leukemia (AML), which is an aggressive disease with a poor outcome.

In the study led by Dr. Richard Lock in Australia, the researchers showed that antibodies targeting cancer stem cells significantly reduced the growth of human AML cells that had been transplanted into immune-deficient mice, mimicking the human disease.

Principle investigator of the study Dr. John Dick, senior scientist at the Ontario Cancer Institute, had previously shown that there is a population of cells within cancer, termed cancer stem cells, which are responsible for sustaining cancer growth.

The antibody targets the CD123 protein (IL-3 receptor a chain) on the cancer stem cells that drive cancer growth.

However, it does not appear to affect normal blood cells. On the basis of this experimental work, a Phase I clinical trial has been initiated to test safety and effectiveness in patients. (ANI)

Gastrin levels vital in bacterial-induced stomach cancer

Washington, June 24 (ANI): Gastrin levels have a very important role to play in the development of Helicobacter-induced stomach cancer, according to a study.

Over 50 percent of the world’s population is infected with Helicobacter pylori, which causes chronic inflammation of the stomach lining, and is strongly linked to the development of gastric ulcers and stomach cancer.

Stomach cancer is the second leading cause of cancer-related deaths worldwide.

Helicobacter infection results in increased expression of gastrin, a hormone that stimulates secretion of gastric acid.

However, the role of gastrin in cancer development still remains unclear.

While high levels of gastrin lead to the development of stomach cancer, but absence of gastrin has been shown to increase the numbers of tumours in the gastric antrum- the lower section of the stomach that empties into the small intestine.

Thus, for explaining this apparent disparity, a group led by Dr. Timothy Wang at the Columbia University Medical Center in New York, NY examined the contribution of Helicobacter infection to gastric cancer in animal models with either high expression of gastrin or no gastrin at all.

It was found that Helicobacter infection in mice with high levels of gastrin resulted in cancer of the gastric corpus (main body of the stomach).

On the other hand, infection in gastrin-deficient mice led to cancer in a different part of the stomach- the gastric antrum.

Thus, the researchers concluded that gastrin plays a key role in the development of Helicobacter-induced stomach cancer, but may have distinct effects on carcinogenesis in different parts of the stomach.

The related report by Takaishi et al, ‘Gastrin is an essential cofactor for Helicobacter-associated gastric corpus carcinogenesis in C57BL/6 mice’, is appearing in the upcoming issue of The American Journal of Pathology. (ANI)

New interferon response could offer early control of bird flu virus

Washington, June 20 (ANI): The cell-signalling protein, interferon type 1, has the potential to reduce H5N1 influenza virus’ (bird flu virus) replication in mice, and can thus offer protection in the early stages of infection, according to researchers from Georgia.

Highly pathogenic avian influenza H5N1 viruses increasingly pose a serious public health risk, as cases of interspecies transmission from birds to humans continue to rise.

While not much is known about the pathogenic mechanisms of H5N1 influenza viruses, prior research has suggested that their ability to evade innate immune responses within the host, such as the type 1 interferon (IFN-a/B) response, contributes to virulence in mammals.

In the study, they used a mouse model to analyse the role of type 1 interferons in IFN a/ receptor-deficient and wild-type mice challenged with two avian influenza A viruses isolated from humans (HK/483 and HK/486).

The two viruses generally exhibit high and low lethality in mice.

The findings revealed that INF-a/ß receptor-deficient mice lost significantly more weight, and were faster to succumb to death than wild-type mice.

Both the HK/483 and H/K 486 virus caused a similar systemic infection in INF-a/ß receptor-deficient mice.

However, pre-treatment with IFN-a/ß significantly reduced replication of both viruses.

“These results suggest a role for the IFN-a/ß response in the control of H5N1 virus replication both in vivo and in vitro, and as such it may provide some degree of protection to the host in the early stages of infection,” said the researchers.

The findings of the study have been reported in the Journal of Virology. (ANI)

Scientists grow blood vessels using stem cells

Washington, April 7 (ANI): Researchers at University of Western Ontario have succeeded in growing new blood vessels using stem cells from bone marrow, a medical advance that could be used to treat patients with diseases such as peripheral artery disease.

It’s one of the severe complications often faced by people who’ve had diabetes for a long time.

Reduced blood flow (ischemia) in their limbs can lead to resting pain, trouble with wound healing and in severe cases, amputation.

During the research, David Hess of the Robarts Research Institute at the university drew human bone marrow and simultaneously isolated three different types of stem cells that co-ordinate together to form new blood vessels. These are called pro-angiogenic stem cells.

They were purified to remove any inflammatory or contaminated cells, and then injected into the circulation of mice, which had one of their leg arteries ligated and removed.

The researchers showed how these stem cells have a natural ability to hone in on the area of ischemia to induce blood vessel repair and improve blood flow.

Hess said that this research is clinically applicable because they studied the function of human stem cells in immune-deficient mice.

The preclinical data from Hess’ research was used by a biopharmaceutical company, Aldagen to receive FDA approval for a multi-center clinical trial now underway in Houston, Texas, involving 21 patients with end-stage peripheral artery disease.

“We can select the right stem cells from the patient’s own bone marrow and put them back in the area of ischemia to allow these cells to coordinate the formation of new blood vessels.” said Hess.

“These principles could be applied not only to ischemic limbs, but to aid in the formation of new blood vessels in ischemic tissue anywhere in the body, for example after a stroke or heart attack,” he added.

The research is published in Blood. (ANI)

Scientists unearth the yin and yang of asthma

London, March 30 (ANI): A study has shed some light on how an enzyme prompts an allergic reaction, and how a vitamin dampens the inflammatory effect, in people with asthma.

A consortium of researchers led by Baylor College of Medicine in Houston found that the allergen breathed in by asthmatics triggers the enzyme MMP7, which activates a cascade of events to prompt an allergic reaction.

Drs. Farrah Kheradmand and David B. Corry, both of whom are associate professors of Medicine-Pulmonary at BCM as well as senior authors of the study report, point out that that MMP7 particularly activates interleukin 25, a key mediator of the allergic response in the lung.

The research team have also found that a form of vitamin A made in the lung is critical for dampening the inflammatory effect.

While experimenting on mice, the researchers observed that the animals lacking MMP7 had higher production of retinal dehydrogenase, an enzyme that is responsible for synthesizing vitamin A in the lung.

They revealed that the MMP7 deficient mice showed less lung inflammation when exposed to allergens, compared to those that had enough of the enzyme.

When the researchers suppressed the production of vitamin A, the asthmatic symptoms in the MMP7 deficient mice were restored.

“It is important to know which mediators in the airway may be setting off the initial cascade of events that result in the asthmatic reaction in the lung; it would be like getting to the top of the food chain,” Nature magazine quoted them as saying.

Kheradmand and Corry hope that future studies will help better understand the relationship between the synthesis of vitamin A in the body and the repression of MMP7. research article on their most recent findings appears online in the journal Nature Immunology. (ANI)

‘Fat controller’ found in the gut

London, Mar 16 (ANI): A team of American scientists has discovered a ‘fat controller’ in the gut that may help fight obesity.

According to researchers, by disabling the enzyme that helps the body to absorb fat, it is possible to prevent weight gain.

The discovery could pave the way for new drug treatments to protect against obesity, and could also help stop the development of high cholesterol and even a fatty liver.

Researchers at the University of California in San Francisco found that the intestinal enzyme MGAT2 plays a crucial role in this energy storage process and the consequent build-up of fat.

They found that by making the enzyme inactive in mice, the animals were able to consume a high-fat diet without putting on weight.

After 16 weeks the MGAT2-deficient mice weighed an incredible 60 per cent less than normal mice, while their fat mass was 50 per cent lower.

The researchers concluded that by disabling MGAT2, the fat the mice consumed was converted into energy rather than stored in the body.

“Since we eat a lot of fat in our diet, if you transfer the fat absorption in a way that the body can tolerate without many side effects, that would be useful,” the Daily Express quoted lead author Professor Bob Farese Jr, professor of medicine and biochemistry at the University of California in San Francisco, said.

“The enzyme is a gatekeeper in the intestine for absorbing fat. e inactivated that in mice to see how effective it was.

“The mice that didn’t have the enzyme were given more fat and the rate of uptake of fat was slowed,” he added.

The study has been published online in Nature Medicine. (ANI)